BI-78D3 25mg | ≥99%
CSNpharm
BI-78D3 is a selective and competitive JNK inhibitor with IC50 of 280 nM.
More Information Supplier Page
BI-78D3 is a selective and competitive JNK inhibitor with IC50 of 280 nM.
More Information Supplier Page
BI-78D3 is a selective and competitive JNK inhibitor with IC50 of 280 nM.
More Information Supplier Page
BI-78D3 is a selective and competitive JNK inhibitor with IC50 of 280 nM.
More Information Supplier Page
BI-78D3 is a selective and competitive JNK inhibitor with IC50 of 280 nM.
More Information Supplier Page
(R)-(-)-rolipram, R-enantiomer of rolipram, is a potent and cAMP-specific PDE4 inhibitor with IC50 of 0.22 μM and 2.5-fold more potent than(+)-rolipram (IC50= 2.58 μM) in inhibiting membrane-bound PDE 4.
More Information Supplier Page
(R)-(-)-rolipram, R-enantiomer of rolipram, is a potent and cAMP-specific PDE4 inhibitor with IC50 of 0.22 μM and 2.5-fold more potent than(+)-rolipram (IC50= 2.58 μM) in inhibiting membrane-bound PDE 4.
More Information Supplier Page
(R)-(-)-rolipram, R-enantiomer of rolipram, is a potent and cAMP-specific PDE4 inhibitor with IC50 of 0.22 μM and 2.5-fold more potent than(+)-rolipram (IC50= 2.58 μM) in inhibiting membrane-bound PDE 4.
More Information Supplier Page
(R)-(-)-rolipram, R-enantiomer of rolipram, is a potent and cAMP-specific PDE4 inhibitor with IC50 of 0.22 μM and 2.5-fold more potent than(+)-rolipram (IC50= 2.58 μM) in inhibiting membrane-bound PDE 4.
More Information Supplier Page
Tauroursodeoxycholate Sodium can suppress ERK via PKCα-mediated MKP-1 induction, thus inhibiting neointimal hyperplasia of smooth muscle cells.
More Information Supplier Page
Tauroursodeoxycholate Sodium can suppress ERK via PKCα-mediated MKP-1 induction, thus inhibiting neointimal hyperplasia of smooth muscle cells.
More Information Supplier Page